CN111196916B - Medical antifogging agent and preparation method thereof - Google Patents
Medical antifogging agent and preparation method thereof Download PDFInfo
- Publication number
- CN111196916B CN111196916B CN201811379805.6A CN201811379805A CN111196916B CN 111196916 B CN111196916 B CN 111196916B CN 201811379805 A CN201811379805 A CN 201811379805A CN 111196916 B CN111196916 B CN 111196916B
- Authority
- CN
- China
- Prior art keywords
- antifogging agent
- medical
- parts
- mixed solution
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Combustion & Propulsion (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
Abstract
The invention provides a medical antifogging agent and a preparation method thereof; comprises the following components in parts by weight: 1.5-2.0 parts of dioctyl sodium sulfosuccinate, 0.05-0.10 part of dodecyl polyoxyethylene ether sodium sulfate, 0.1-0.3 part of ethanol, 4.0-4.5 parts of isopropanol, 93.0-94.0 parts of water, 0.5-0.7 part of sodium silicate solution and 0.03-0.05 part of glycerol. The preparation method of the medical antifogging agent comprises the following steps: step one, heating the water to 30-40 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A; step two, mixing a sodium silicate solution and glycerol to obtain a mixed solution B; and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent. The antifogging agent related by the invention has stable product performance, can be used on various endoscope probe mirror surfaces in the medical field, and has wide application range; the use effect is obvious; the preparation method provided by the invention is simple in process.
Description
Technical Field
The invention belongs to the field of medical antifogging agents; in particular to a medical antifogging agent and a preparation method thereof.
Background
As is known, an endoscope is an optical imaging device for minimally invasive medical examinations, which can be introduced into the body through natural orifices of the body or through small surgical incisions. The endoscope can be used for seeing the pathological changes which cannot be displayed by X-rays, and can effectively assist doctors to make definite diagnosis on the diseases. For example, a physician may view an ulcer or tumor in the stomach with the aid of an endoscope, and work out an optimal treatment plan accordingly.
In recent years, endoscopes have been widely used in medical fields such as digestive medicine, respiratory medicine, orthopedics, neurosurgery, hepatobiliary surgery, and urology. The endoscope sends the head end objective lens to a part to be examined and diagnosed in a body through the insertion part, and observes tissues and organs in the body of the examined person.
The endoscope can keep clear and accurate imaging of an objective lens in the process of observing tissues and organs and diagnosing diseases, and is a basic and principal principle of application in the medical field. However, due to the temperature difference between the objective lens of the endoscope and the human body, the surface of the objective lens is easily covered by the liquefied water vapor in a atomized manner, which causes the results of blurred vision and deformation of the observed image of the objective lens, which will seriously affect the normal use of the endoscope by medical staff and even the correct diagnosis of diseases by doctors.
Based on the technical problems, the medical antifogging agent can be coated on the surface of the medical endoscope probe lens, and the technical problems can be effectively solved.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a medical antifogging agent and a preparation method thereof.
In a first aspect, the invention is realized by the following technical scheme: the medical antifogging agent comprises the following components in parts by weight:
1.5 to 2.0 portions of dioctyl sodium sulfosuccinate,
0.05 to 0.10 portion of sodium dodecyl polyoxyethylene ether sulfate,
0.1 to 0.3 portion of ethanol,
4.0 to 4.5 portions of isopropanol,
93.0 to 94.0 portions of water,
0.5 to 0.7 portion of sodium silicate solution,
0.03-0.05 part of glycerol.
Preferably, the composition comprises the following components in parts by weight:
1.8 to 2.0 portions of dioctyl sodium sulfosuccinate,
0.08 to 0.10 portion of sodium dodecyl polyoxyethylene ether sulfate,
0.2 to 0.3 portion of ethanol,
4.3 to 4.5 portions of isopropanol,
93.5 to 94.0 portions of water,
0.5 to 0.7 portion of sodium silicate solution,
0.04-0.05 part of glycerol.
Preferably, the dioctyl sodium sulfosuccinate is obtained by reacting diisooctyl maleate with sodium metabisulfite; the method specifically comprises the following steps:
step one, sequentially putting 280 plus or minus 5kg of maleic anhydride, 100 plus or minus 5kg of secondary octanol and 2 plus or minus 0.5kg of sulfuric acid into a reaction kettle, refluxing under reduced pressure, dividing water by a water separator, and taking the acid value to 2 plus or minus 0.3kgkoH/g as a terminal point;
step two, transferring the feed liquid into a neutralization kettle, separating a water layer, performing reduced pressure dealcoholization distillation, raising the temperature to 160 +/-10 ℃, and stopping heating;
step three, adding 1000 plus or minus 5kg of water and 312 plus or minus 8kg of NaHSO3, pumping out the air in the kettle, sealing the sulfonation kettle, reacting for 6 +/-1 h under 0.1-0.25 MPa, standing and layering.
The method of the invention adopts environment-friendly solid heteropoly acid as the catalyst, the conversion can reach more than 96 percent, the catalyst is easy to recover, and the catalyst can be repeatedly used for 6 times.
In the step of the invention, naHO3 is used as a sulfonating agent in the sulfonation reaction, and the sulfonation kettle is sealed, thereby reducing the environmental pollution.
Preferably, the sodium silicate solution is a sodium silicate aqueous solution with the mass fraction of 20%.
Preferably, the CAS number of the sodium laureth sulfate is AES.
Preferably, the ethanol has a CAS number of 64-17-5.
Preferably, the CAS number of the isopropanol is 67-63-0.
Preferably, the water is deionized water.
Preferably, the medical antifogging agent further comprises 0.1-1 part by weight of an auxiliary antifogging agent, and the auxiliary antifogging agent is a lauric acid modified MCM-41 molecular sieve.
Preferably, the preparation method of the lauric acid modified MCM-41 molecular sieve comprises the following steps:
weighing 1g of KH570, 10g of MCM-41 molecular sieve, 2g of lauric acid, 0.2g of toluenesulfonic acid, 10ml of toluene and 100ml of dimethyl sulfoxide in a reactor, heating to 80 ℃ for reaction for 5 hours, pouring the reaction solution into acetone to obtain a large amount of precipitate, filtering and drying the precipitate to obtain the lauric acid modified MCM-41 molecular sieve.
In a second aspect, the present invention also relates to a preparation method of the medical antifogging agent, which comprises the following steps:
step one, heating the water to 30-40 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing the sodium silicate solution and glycerol to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in the first step, the stirring time is 1-2 hours.
Preferably, in the second step, the stirring time is 1-3 hours.
Due to the adoption of the scheme, the invention has the beneficial effects that:
the antifogging agent related by the invention has stable product performance and obvious use effect;
the invention can be used on various endoscope probe mirror surfaces in the medical field, and has wide application range;
the antifogging agent is prepared from raw materials directly purchased from the market;
the preparation method provided by the invention is simple in process.
(5) The method of the invention adopts environment-friendly solid heteropoly acid as the catalyst, the conversion can reach more than 96 percent, the catalyst is easy to recover, and the catalyst can be repeatedly used for 6 times.
(6) In the step of the invention, naHO3 is used as a sulfonating agent in the sulfonation reaction, and the sulfonation kettle is sealed, so that the environmental pollution is reduced;
(7) The addition of the lauric acid modified MCM-41 molecular sieve can effectively prolong the antifogging time and improve the mirror definition.
Drawings
FIG. 1 is a graph showing the effect of the test in example 1 by the rapid thermal spraying method;
FIG. 2 is a graph showing the effect of example 2 in the rapid thermal spray test;
FIG. 3 is a graph showing the effect of example 3 measured by the rapid thermal spray method;
FIG. 4 is a graph showing the effect of the test of example 4 by the rapid thermal spraying method;
FIG. 5 is a graph showing the effect of the test in example 5 by the rapid thermal spraying method;
FIG. 6 is a graph showing the effect of the test of example 6 by the rapid thermal spraying method;
FIG. 7 is a graph showing the effect of example 7 in the rapid thermal spraying test;
FIG. 8 is a graph showing the effect of comparative example 1 measured by the rapid thermal spray method;
FIG. 9 is a graph showing the effect of comparative example 2 measured by the rapid thermal spray method.
Detailed Description
The present invention will be described in detail with reference to specific examples. It should be noted that the following examples are only intended to illustrate the present invention, but the scope of the present invention is not limited to the following examples.
Raw materials:
unless otherwise indicated, the starting materials of the present invention are commercially available, with MCM-41 molecular sieves being available from Shandong Dengzpin chemical Co. Other materials were purchased from Aladdin reagents, inc.
Example 1
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
1.5 parts of dioctyl sodium sulfosuccinate,
0.05 part of sodium dodecyl polyoxyethylene ether sulfate,
0.1 part of ethanol, namely,
4.0 parts of isopropanol, namely 4.0 parts of isopropanol,
93.0 parts of deionized water, and the like,
0.5 part of sodium silicate aqueous solution (mass fraction is 20%),
0.03 part of glycerol.
The preparation method of the medical antifogging agent related to the embodiment comprises the following steps:
step one, heating the water to 30 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in the first step, the stirring time is 1 hour.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 1 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 1.
Example 2
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
2.0 parts of dioctyl sodium sulfosuccinate,
0.10 part of sodium dodecyl polyoxyethylene ether sulfate,
0.3 part of ethanol, namely, ethanol,
4.5 parts of isopropanol, namely 4.5 parts of isopropanol,
94.0 parts of deionized water, namely,
0.7 part of sodium silicate aqueous solution (mass fraction is 20%),
0.05 part of glycerol.
The preparation method of the medical antifogging agent designed in the embodiment comprises the following steps:
step one, heating the water to 40 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in step one, the stirring time is 2 hours.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 2 is coated on the surface of the lens of the medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 2.
Example 3
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
1.6 parts of dioctyl sodium sulfosuccinate,
0.07 part of sodium dodecyl polyoxyethylene ether sulfate,
0.15 part of ethanol, namely,
4.2 parts of isopropanol, namely 4.2 parts of isopropanol,
93.3 parts of deionized water, wherein,
0.6 part of sodium silicate aqueous solution (mass fraction is 20%),
0.04 part of glycerol.
The preparation method of the medical antifogging agent related to the embodiment comprises the following steps:
step one, heating the water to 35 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol in proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B into the mixture, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in the first step, the stirring time is 1 hour.
Preferably, in the second step, the stirring time is 2 hours.
The medical antifogging agent obtained in the embodiment 3 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 3.
Example 4
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
1.8 parts of dioctyl sodium sulfosuccinate,
0.08 part of sodium dodecyl polyoxyethylene ether sulfate,
0.2 part of ethanol, namely, ethanol,
4.3 parts of isopropanol, namely, 4.3 parts of isopropanol,
93.5 parts of deionized water, wherein,
0.5 part of sodium silicate aqueous solution (mass fraction is 20%),
0.03 part of glycerol.
The preparation method of the medical antifogging agent related to the embodiment comprises the following steps:
step one, heating the water to 37 ℃, adding dioctyl sodium sulfosuccinate and dodecyl polyoxyethylene ether sodium sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in step one, the stirring time is 2 hours.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 4 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 4.
Example 5
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
1.7 parts of dioctyl sodium sulfosuccinate,
0.09 part of sodium dodecyl polyoxyethylene ether sulfate,
0.15 part of ethanol, namely,
4.2 parts of isopropanol, namely 4.2 parts of isopropanol,
93.5 parts of deionized water, wherein,
0.7 part of sodium silicate aqueous solution (mass fraction is 20%),
0.05 part of glycerol.
The preparation method of the medical antifogging agent related to the embodiment comprises the following steps:
step one, heating the water to 38 ℃, adding dioctyl sodium sulfosuccinate and dodecyl polyoxyethylene ether sodium sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in step one, the stirring time is 2 hours.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 5 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 5.
Example 6
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
2.0 parts of dioctyl sodium sulfosuccinate,
0.10 part of sodium dodecyl polyoxyethylene ether sulfate,
0.3 part of ethanol, namely,
4.5 parts of isopropanol, namely 4.5 parts of isopropanol,
94.0 parts of deionized water, namely,
0.7 part of sodium silicate aqueous solution (mass fraction is 20%),
0.05 part of glycerol
0.2 part of lauric acid modified MCM-41 molecular sieve.
The preparation method of the lauric acid modified MCM-41 molecular sieve comprises the following steps:
in a reactor, weighing 1g of KH570, 10g of MCM-41 molecular sieve, 2g of lauric acid, 0.2g of toluenesulfonic acid, 10ml of toluene and 100ml of dimethyl sulfoxide, heating to 80 ℃ for reaction for 5 hours, pouring the reaction solution into acetone to obtain a large amount of precipitate, filtering and drying the precipitate to obtain the lauric acid modified MCM-41 molecular sieve.
The preparation method of the medical antifogging agent designed in the embodiment comprises the following steps:
step one, heating the water to 40 ℃, adding dioctyl sodium sulfosuccinate, sodium dodecyl polyoxyethylene ether sulfate and a lauric acid modified MCM-41 molecular sieve in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B into the mixture, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in step one, the stirring time is 2 hours.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 6 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance of the alloy is evaluated by using a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 6.
Example 7
The embodiment relates to a medical antifogging agent which comprises the following components in parts by weight:
2.0 parts of dioctyl sodium sulfosuccinate,
0.10 part of sodium dodecyl polyoxyethylene ether sulfate,
0.3 part of ethanol, namely,
4.5 parts of isopropanol, namely 4.5 parts of isopropanol,
94.0 parts of deionized water, namely,
0.7 part of sodium silicate aqueous solution (mass fraction is 20%),
0.05 part of glycerol
0.2 part of lauric acid modified MCM-41 molecular sieve.
Wherein the dioctyl sodium sulfosuccinate is obtained by reacting diisooctyl maleate with sodium metabisulfite; the method specifically comprises the following steps:
step one, sequentially putting 280kg of maleic anhydride, 100kg of secondary octanol and 2kg of sulfuric acid into a reaction kettle, refluxing under reduced pressure, dividing water by using a water separator, and taking the acid value to 2 kgkoH/g as a terminal point;
step two, moving the feed liquid into a neutralization kettle, separating out a water layer, decompressing, dealcoholizing, distilling, raising the temperature to 160 ℃, and stopping heating;
and step three, adding 1000kg of water and 312kg of NaHSO3, pumping out the air in the reactor, sealing the sulfonation reactor, reacting for 6 hours under 0.1MPa, standing and layering to obtain the catalyst.
The preparation method of the lauric acid modified MCM-41 molecular sieve comprises the following steps:
weighing 1g of KH570, 10g of MCM-41 molecular sieve, 2g of lauric acid, 0.2g of toluenesulfonic acid, 10ml of toluene and 100ml of dimethyl sulfoxide in a reactor, heating to 80 ℃ for reaction for 5 hours, pouring the reaction solution into acetone to obtain a large amount of precipitate, filtering and drying the precipitate to obtain the lauric acid modified MCM-41 molecular sieve.
The preparation method of the medical antifogging agent designed in the embodiment comprises the following steps:
step one, heating the water to 40 ℃, adding dioctyl sodium sulfosuccinate, dodecyl polyoxyethylene ether sodium sulfate and a lauric acid modified MCM-41 molecular sieve in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate aqueous solution (mass fraction is 20%) with glycerol according to a proportion to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
Preferably, in step one, the stirring time is 2 hours.
Preferably, in the second step, the stirring time is 1 hour.
The medical antifogging agent obtained in the embodiment 7 is coated on the surface of a lens of a medical endoscope, and the thickness of the antifogging agent is hundreds of nanometers; the evaluation method of the antifogging performance is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 7.
Comparative example 1
The comparative example relates to a medical antifogging agent which comprises the following components in parts by weight:
1.0 part of dioctyl sodium sulfosuccinate,
0.01 part of sodium dodecyl polyoxyethylene ether sulfate,
0.1 part of ethanol, namely, ethanol,
4.0 parts of isopropanol, namely 4.0 parts of isopropanol,
93.0 parts of deionized water.
Wherein the CAS number of the dioctyl sodium sulfosuccinate described in this comparative example is wetting agent OT.
The preparation method of the medical antifogging agent of the comparative example can refer to the preparation methods of examples 1 to 7;
coating the medical antifogging agent obtained in the comparative example 1 on the surface of the lens of the medical endoscope, wherein the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance evaluation method is tested by a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 8.
Comparative example 2
The comparative example relates to a medical antifogging agent which comprises the following components in parts by weight:
1.3 parts of dioctyl sodium sulfosuccinate,
0.02 part of sodium dodecyl polyoxyethylene ether sulfate,
93.0 parts of deionized water.
The CAS number of sodium dioctyl sulfosuccinate described in this example is the wetting agent OT.
The CAS number of the sodium dodecyl polyoxyethylene ether sulfate is AES.
The method for preparing the medical antifogging agent of this comparative example refers to the methods of examples 1 to 7;
coating the medical antifogging agent obtained in the comparative example 2 on the surface of the lens of the medical endoscope, wherein the thickness of the antifogging agent is hundreds of nanometers; the antifogging performance of the alloy is evaluated by using a water bath hot fogging method and a rapid hot fogging method according to GB/T31726-2015, and the result is shown in figure 9.
The CAS number of the dioctyl sodium sulfosuccinate referred to in this comparative example 1-2 is the wetting agent OT.
The following experiments were performed on the medical antifogging agents prepared in the above examples 1 to 7 of the present invention and comparative examples 1 to 2, and the following experiments were performed, as shown in table 1:
TABLE 1
The data from table 1 above show that: the medical antifogging agent obtained in the embodiments 1 to 7 of the invention has a product grade of 1 to 2 grade, and is shown by a rapid hot fogging method test, and the test result of the medical antifogging agent is clearly shown in the figures 1 to 7; compared with the prior art, the effects of the comparative examples 1 to 2 are far lower than the using effect of the antifogging agent disclosed by the invention; therefore, the antifogging agent effectively solves the problems that the imaging definition and accuracy are influenced and the doctor is disturbed to make effective and correct diagnosis because water mist is generated by the difference of the internal temperature and the external temperature of the objective lens of the endoscope, so that the medical antifogging agent plays an extremely important role in the use of the endoscope in the medical field.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes or modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Claims (9)
1. The medical antifogging agent is characterized by comprising the following components in parts by weight:
1.5-2.0 parts of dioctyl sodium sulfosuccinate,
0.05 to 0.10 portion of sodium dodecyl polyoxyethylene ether sulfate,
0.1 to 0.3 portion of ethanol,
4.0 to 4.5 portions of isopropanol,
93.0 to 94.0 portions of deionized water,
0.5 to 0.7 portion of sodium silicate solution,
0.03-0.05 part of glycerol.
2. The medical antifogging agent of claim 1, comprising the following components by weight:
1.8 to 2.0 portions of dioctyl sodium sulfosuccinate,
0.08 to 0.10 portion of sodium dodecyl polyoxyethylene ether sulfate,
0.2 to 0.3 portion of ethanol,
4.3 to 4.5 portions of isopropanol,
93.5 to 94.0 portions of deionized water,
0.5 to 0.7 portion of sodium silicate solution,
0.04-0.05 part of glycerol.
3. The medical antifogging agent of claim 1, wherein said dioctyl sodium sulfosuccinate is obtained by reacting diisooctyl maleate with sodium metabisulfite; the method specifically comprises the following steps:
step one, sequentially putting 280 plus or minus 5kg of maleic anhydride, 100 plus or minus 5kg of secondary octanol and 2 plus or minus 0.5kg of sulfuric acid into a reaction kettle, refluxing under reduced pressure, dividing water by a water separator, and taking the acid value to 2 plus or minus 0.3kgkoH/g as a terminal point;
step two, transferring the feed liquid into a neutralization kettle, separating a water layer, performing reduced pressure dealcoholization distillation, raising the temperature to 160 +/-10 ℃, and stopping heating;
step three, adding 1000 plus or minus 5kg of water and 312 plus or minus 8kg of NaHSO3, pumping out the air in the kettle, sealing the sulfonation kettle, reacting for 6 +/-1 h under 0.1-0.25 MPa, standing and layering.
4. The medical antifog agent of claim 1, wherein said ethanol has a CAS number of 64-17-5.
5. The medical antifog agent of claim 1, wherein said isopropyl alcohol has a CAS number of 67-63-0.
6. The medical antifogging agent of claim 1, further comprising 0.1-1 parts by weight of an auxiliary antifogging agent, wherein the auxiliary antifogging agent is a lauric acid modified MCM-41 molecular sieve.
7. A method for preparing the medical antifogging agent according to claim 1, characterized in that it comprises the following steps:
step one, heating the deionized water to 30-40 ℃, adding dioctyl sodium sulfosuccinate and sodium dodecyl polyoxyethylene ether sulfate in proportion, and stirring and mixing uniformly to obtain a mixed solution A;
step two, mixing a sodium silicate solution and glycerol to obtain a mixed solution B;
and step three, mixing ethanol and isopropanol in proportion, adding the mixture into the mixed solution A, pouring the mixed solution B, and stirring the mixture uniformly to obtain the medical antifogging agent.
8. The method for preparing the medical antifogging agent of claim 7, wherein in the first step, the stirring time is 1 to 2 hours.
9. The method for preparing the medical antifogging agent according to claim 7, wherein the stirring time in the second step is 1 to 3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811379805.6A CN111196916B (en) | 2018-11-20 | 2018-11-20 | Medical antifogging agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811379805.6A CN111196916B (en) | 2018-11-20 | 2018-11-20 | Medical antifogging agent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111196916A CN111196916A (en) | 2020-05-26 |
| CN111196916B true CN111196916B (en) | 2022-11-18 |
Family
ID=70744137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811379805.6A Active CN111196916B (en) | 2018-11-20 | 2018-11-20 | Medical antifogging agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111196916B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115353860B (en) * | 2022-09-22 | 2024-01-02 | 大连恢宏科技有限公司 | Medical endoscope antifogging agent |
| CN117511504B (en) * | 2024-01-04 | 2024-03-26 | 荷塘探索国际健康科技发展（北京）有限公司 | Medical antifogging agent, preparation method and antifogging mirror cloth prepared from medical antifogging agent |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN102260482A (en) * | 2010-11-01 | 2011-11-30 | 中南大学肝胆肠外科研究中心 | Polymer type antifogging agent for optical lens and preparation method thereof |
| CN102321451A (en) * | 2011-10-13 | 2012-01-18 | 上海嘉华广告有限公司 | Antifogging agent special for advertising board |
| CN102703029A (en) * | 2012-06-18 | 2012-10-03 | 桑达化工（南通）有限公司 | Antifogging agent for glass |
| CN103409110A (en) * | 2013-08-20 | 2013-11-27 | 南通市通州区益君劳务有限公司 | Cleaning and antifogging agent for glass |
| CN103881658A (en) * | 2014-03-12 | 2014-06-25 | 福建省石狮市通达电器有限公司 | Antifogging agent |
| CN103952123A (en) * | 2014-05-23 | 2014-07-30 | 江苏紫石化工科技有限公司 | Glass detergent |
| CN104212412A (en) * | 2014-08-29 | 2014-12-17 | 青岛文晟汽车零部件有限公司 | Improved frost and fog preventing agent for automobile glass |
| CN104497975A (en) * | 2014-11-26 | 2015-04-08 | 青岛崂乡茶制品有限公司 | Outdoor show-window antifogging agent |
| CN107541190A (en) * | 2017-09-06 | 2018-01-05 | 苏州纽东精密制造科技有限公司 | A kind of anti-fog agent for wind-screen of automobile and preparation method thereof |
| CN108441170A (en) * | 2018-04-19 | 2018-08-24 | 岳宜霞 | A kind of new-energy automobile antifoggant |
-
2018
- 2018-11-20 CN CN201811379805.6A patent/CN111196916B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN102260482A (en) * | 2010-11-01 | 2011-11-30 | 中南大学肝胆肠外科研究中心 | Polymer type antifogging agent for optical lens and preparation method thereof |
| CN102321451A (en) * | 2011-10-13 | 2012-01-18 | 上海嘉华广告有限公司 | Antifogging agent special for advertising board |
| CN102703029A (en) * | 2012-06-18 | 2012-10-03 | 桑达化工（南通）有限公司 | Antifogging agent for glass |
| CN103409110A (en) * | 2013-08-20 | 2013-11-27 | 南通市通州区益君劳务有限公司 | Cleaning and antifogging agent for glass |
| CN103881658A (en) * | 2014-03-12 | 2014-06-25 | 福建省石狮市通达电器有限公司 | Antifogging agent |
| CN103952123A (en) * | 2014-05-23 | 2014-07-30 | 江苏紫石化工科技有限公司 | Glass detergent |
| CN104212412A (en) * | 2014-08-29 | 2014-12-17 | 青岛文晟汽车零部件有限公司 | Improved frost and fog preventing agent for automobile glass |
| CN104497975A (en) * | 2014-11-26 | 2015-04-08 | 青岛崂乡茶制品有限公司 | Outdoor show-window antifogging agent |
| CN107541190A (en) * | 2017-09-06 | 2018-01-05 | 苏州纽东精密制造科技有限公司 | A kind of anti-fog agent for wind-screen of automobile and preparation method thereof |
| CN108441170A (en) * | 2018-04-19 | 2018-08-24 | 岳宜霞 | A kind of new-energy automobile antifoggant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111196916A (en) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111196916B (en) | Medical antifogging agent and preparation method thereof | |
| AU2019410432A1 (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| KR20080027191A (en) | New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same | |
| Dorland | The American illustrated medical dictionary | |
| CN113652050A (en) | Hydrogel film, preparation method thereof and ultrasonic coupling patch | |
| CN110257759B (en) | Method for processing stainless steel with excellent biocompatibility | |
| CN109913073B (en) | Super-hydrophilic coating for medical endoscope lens and preparation method thereof | |
| RU2415876C1 (en) | N-vinylpyrrolidone based copolymers | |
| EA031316B1 (en) | Method for producing a copolymer of sodium carboxymethyl cellulose and gossypol | |
| CN109988074A (en) | A kind of preparation method being suitble to medicinal terbutaline sulphate crystal B | |
| CN115232064A (en) | Synthesis of amphiphilic double-site receptor and identification of ATP and biological thiol by fluorescent indicator displacement method of amphiphilic double-site receptor | |
| CN105566303A (en) | Novel daclatasvir crystal form and preparing method thereof | |
| CN112569182A (en) | Aluminum sulfate compound injection and preparation method and application thereof | |
| CN115353860B (en) | Medical endoscope antifogging agent | |
| CN112094317A (en) | His-Gly-Lys modified methotrexate, synthesis, anti-transfer activity and application thereof | |
| ES2942312T3 (en) | tert-Butyl ester hydrolysis method used in gadolinium contrast agent | |
| CN103990153A (en) | Sterilization and disinfection type medical ultrasonic coupling agent formula and preparation process thereof | |
| CN104211756B (en) | 2 amino 1,3 propanediol derivative, its preparation, nanostructured, Plumbum removing activity and application | |
| CN115068701B (en) | Degradable ureteral stent and preparation method thereof | |
| CN113372384B (en) | Magnetic resonance contrast agent and preparation method and application thereof | |
| CN108478829A (en) | A kind of orthopaedics disinfect box | |
| Marleni et al. | Asuhan Kebidanan Pemeriksaan Fisik Pada Ny. A Ibu Hamil Dengan Post Date Di Puskesmas Baloi Permai | |
| CN106074615B (en) | Gastrointestinal hemostasis defoaming bacteriostatic agent and preparation method thereof | |
| CN110237274A (en) | Visual coronary artery developer and preparation method thereof | |
| CN109223779A (en) | A kind of pharmaceutical composition and its preparation method and application promoting union |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230519 Address after: Room 315 A, Building 1, No. 288 Wuhua Road, Hongkou District, Shanghai, 200086 Patentee after: SHANGHAI XINCHANG MEMORY ALLOY TECHNOLOGY CO.,LTD. Address before: 200086 Room 315 B, Building 1, No. 288, Wuhua Road, Hongkou District, Shanghai Patentee before: Shanghai Xinguang Medical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |